FDA’s Postmarket Drug Safety Pilot Will Consider Between Five And 10 Drugs
Executive Summary
FDA expects to begin in March to develop the first safety profile under a pilot program for postmarket monitoring of new molecular entities
You may also be interested in...
FDA Safety Pilot Prompts SNRI Relabeling; “Too Soon To Tell” Patient Impact
FDA's pilot program to conduct post-market safety reviews of new molecular entities has catalyzed labeling changes for Lilly's Cymbalta, but its impact on patient safety remains uncertain
FDA Safety Pilot Prompts SNRI Relabeling; “Too Soon To Tell” Patient Impact
FDA's pilot program to conduct post-market safety reviews of new molecular entities has catalyzed labeling changes for Lilly's Cymbalta, but its impact on patient safety remains uncertain
Two Postmarket NME Safety Reviews Done; Five To Be Finished By Early ’08
FDA has completed safety reviews for two new molecular entities as part of a pilot program to determine whether preparing postmarket safety profiles would enhance the existing system for monitoring adverse events